Vivid Genomics

Vivid Genomics was a health technology company focused on developing non-invasive genomic tools to improve the diagnosis and treatment of neurodegenerative diseases, particularly Alzheimer's disease. The company utilized a proprietary platform that combined genomics and machine learning to identify patient sub-populations, predict drug response, and monitor disease progression. Their technology aimed to de-risk clinical trials by selecting the right patients for specific therapeutic mechanisms. In 2021, Vivid Genomics was acquired by Verge Genomics to integrate its genomic screening capabilities into Verge's drug discovery pipeline.